Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 7/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | RARA | P10276 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PLK1 | P53350 | 1/20 | 0.54 |
| ▸ | THRA | P10827 | 5/20 | 0.53 |
| ▸ | THRB | P10828 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8902478 | 0.95 | RARB (0.59) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL8903662 | 0.90 | RARB (0.60) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL8145625 | 0.90 | RARB (0.53) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL195471 | 0.88 | THRA (0.61) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL9667335 | 0.88 | THRA (0.61) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL9667123 | 0.88 | THRA (0.61) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL9667265 | 0.88 | THRA (0.61) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL9667141 | 0.88 | THRA (0.61) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL9668006 | 0.88 | THRA (0.61) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL12044522 | 0.88 | THRA (0.61) | RARBALDH1A1MEN1RARAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279733-B2 | Peptide antibiotics | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-03-22 | — | — | US | disclosed |
| US-20200361994-A1 | PEPTIDE ANTIBIOTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361994-A1 | PEPTIDE ANTIBIOTICS | NGLY1, VIP, PEPD | RARB 4505/4885ALDH1A1 4862/4885MEN1 865/4885 |
| US-11279733-B2 | Peptide antibiotics | NGLY1, VIP, PEPD | RARB 4505/4885ALDH1A1 4862/4885MEN1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.